Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62nd Annual ESPE Meeting 2024
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62nd Annual ESPE Meeting 2024
AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company's Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK.
德克薩斯州奧斯汀，2024年10月30日（環球新聞社） - lumos pharma（納斯達克股票代碼：LUMO）是一家臨床階段的生物製藥公司，專注於罕見病治療，今天宣佈該公司第2期OraGrowtH210和OraGrowtH212臨床試驗數據的更新分析已被接受，將在2024年11月16日至18日在英國利物浦舉辦的第62屆歐洲兒科內分泌學會議（ESPE 2024）上進行口頭報告。
Two abstracts on data from the OraGrowtH Trials evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on Sunday, November 17th, by Elżbieta Petriczko, MD, PhD, Pomeranian Medical University, Szczecin, Poland, and on Monday, November 18th, by Peter E. Clayton, MD, University of Manchester, Manchester, UK, respectively.
兩份關於OraGrowtH試驗數據的摘要評估兒童生長激素缺乏症（PGHD）口服LUm-201的報告將由波美拉尼亞斯茲切欣波美拉尼亞醫科大學Elżbieta Petriczko博士於11月17日（星期日）、由曼徹斯特大學曼徹斯特醫學博士Peter E. Clayton博士於11月18日（星期一）分別進行。
LUM-201 Oral Abstract Presentations:
LUm-201口服摘要報告：
Sunday, November 17th – Session: Free Communications 7: GH and IGFs – 10:50AM Local Time
星期日，11月17日 - 會議：自由交流7：GH和IGFs - 上午10:50當地時間
- FC7.6 Abstract entitled, Growth, IGF-1 and IGFBP-3 Responses to Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Pediatric Growth Hormone Deficiency (PGHD) Over 12 to 24 Months on Treatment (Elżbieta Petriczko, MD, PhD, et al)
- 在兒童生長激素缺乏（PGHD）治療過程中，口服lumos pharma LUm-201對OraGrowtH210和OraGrowtH212試驗中的生長、IGF-1和IGFBP-3反應在12至24個月內進行了研究（Elżbieta Petriczko, 醫學博士，博士等）
Monday, November 18th – Session: Free Communications 15: Late Breaking – 9:40AM Local Time
週一，11月18日 - 專題：自由通信15：晚間消息 - 早上9:40當地時間
- FC15.2 Abstract entitled, Amount and Pattern of Pulsatile GH Secretion Induced by the Oral Growth Hormone Secretagogue LUM-201 Is Related to Growth and IGF-1 Responses in Moderate Pediatric Growth Hormone Deficiency (PGHD) (Peter E. Clayton, MD, et al)
- 在中度兒童生長激素缺乏（PGHD）中，口服生長激素促分泌劑lumos pharma LUm-201誘導的脈衝GH分泌的數量和模式與生長和IGF-1反應相關（Peter E. Clayton, 醫學博士等）
About Lumos Pharma
關於Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma's lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit .
路莫斯製藥公司是一家臨床階段的生物製藥公司，專注於罕見病治療藥物的研發和商業化。公司由一支在罕見病藥物研發方面擁有長期經驗的管理團隊創立和領導。路莫斯製藥的主要治療候選藥物LUm-201是一種新型的口服生長激素（GH）分泌劑，旨在將全球價值約47億美元的GH市場從注射劑轉化爲口服治療。LUm-201目前正在多項2期臨床研究中評估用於兒童生長激素缺乏症（PGHD）並已在美國和歐盟均獲得了孤兒藥物認證。有關更多信息，請訪問該公司的網站。
Investor & Media Contact:
投資者及媒體聯繫方式： Lisa Miller Lumos Pharma投資者 Relations 512-792-5454 ir@lumos-pharma.com 來源：Lumos Pharma, Inc。
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Lisa Miller
Lumos Pharma投資者 Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
來源：Lumos Pharma, Inc。
譯文內容由第三人軟體翻譯。
